Patent · US Active

Anti-human NGF antibodies and methods using same

US11655292B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

AMPSOURCE BIOPHARMA SHANGHAI INC. · CN

Inventors

Zhu Wang · Princeton, US
Yongjuan Gao · Shanghai, CN
Si Chen · Pearland, US
Cecily Rou-Yun Sun · Bellaire, US
Yuncheng Zheng · Shanghai, CN
Bill N. C. Sun · Bellaire, US
Qiang Li · Beijing, CN

Key dates

Filing date	Jun 23, 2020
Grant date	May 23, 2023
Priority date	—
Expiry date	Jun 23, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides an antibody and/or an antigen binding fragment that binds to NGF, and the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody and/or its antigen binding fragment provided by the invention has high affinity for NGF and can effectively block the binding between NGF receptor and NGF. This antibody and/or its antigen binding fragment can inhibit the binding activity of NGF and its receptor in vitro, and is suitable for the treatment of pain diseases which are related to the haughty expression or increased expression of NGF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.